| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
83.86(B) |
| Last
Volume: |
1,049,306 |
Avg
Vol: |
801,991 |
| 52
Week Range: |
$483.07 - $787.32 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 963 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 4 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
7,691 |
7,691 |
7,691 |
281,308 |
| Total Sell Value |
$5,103,511 |
$5,103,511 |
$5,103,511 |
$278,226,948 |
| Total People Sold |
3 |
3 |
3 |
15 |
| Total Sell Transactions |
3 |
3 |
3 |
59 |
| End Date |
2025-10-09 |
2025-07-08 |
2025-01-07 |
2024-01-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bassler Bonnie L |
Director |
– • – |
2026-01-07 |
4 |
AS |
$800.00 |
$1,200,000 |
D/D |
(1,500) |
1,703 |
|
- |
|
| Bassler Bonnie L |
Director |
– • – |
2026-01-07 |
4 |
OE |
$374.12 |
$561,180 |
D/D |
1,500 |
3,203 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
155 |
1,703 |
|
- |
|
| Poon Christine A |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
155 |
5,219 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
155 |
6,703 |
|
- |
|
| Sing George L |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
155 |
31,007 |
|
- |
|
| Schenkein David P |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
155 |
603 |
|
- |
|
| Guarini Kathryn |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
155 |
603 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
155 |
17,903 |
|
- |
|
| Coles N Anthony |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
155 |
1,714 |
|
- |
|
| Thompson Craig B. |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
155 |
775 |
|
- |
|
| Bassler Bonnie L |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
155 |
1,703 |
|
- |
|
| Zoghbi Huda Y |
Director |
– • – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
155 |
1,703 |
|
- |
|
| Schleifer Leonard S |
Bd. Co-Chair, President & CEO |
• • – |
2025-12-31 |
4 |
D |
$772.09 |
$22,058,611 |
D/D |
(28,570) |
214,523 |
|
- |
|
| Schleifer Leonard S |
Bd. Co-Chair, President & CEO |
• • – |
2025-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
28,570 |
243,093 |
|
- |
|
| Yancopoulos George |
Bd. Co-Chair, President & CSO |
• • – |
2025-12-31 |
4 |
D |
$772.09 |
$22,058,611 |
D/D |
(28,570) |
310,460 |
|
- |
|
| Yancopoulos George |
Bd. Co-Chair, President & CSO |
• • – |
2025-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
28,570 |
339,030 |
|
- |
|
| Sing George L |
Director |
– • – |
2025-12-30 |
4 |
D |
$774.03 |
$4,789,698 |
D/D |
(6,188) |
30,852 |
|
- |
|
| Sing George L |
Director |
– • – |
2025-12-30 |
4 |
OE |
$520.01 |
$4,790,332 |
D/D |
9,212 |
37,040 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2025-12-09 |
4 |
D |
$701.51 |
$2,966,686 |
D/D |
(4,229) |
47,833 |
|
- |
|
| Schleifer Leonard S |
Bd. Co-Chair, President & CEO |
• • – |
2025-12-09 |
4 |
D |
$701.51 |
$108,835,769 |
D/D |
(155,145) |
214,523 |
|
- |
|
| Schleifer Leonard S |
Bd. Co-Chair, President & CEO |
• • – |
2025-12-09 |
4 |
OE |
$555.67 |
$95,976,989 |
D/D |
172,723 |
369,668 |
|
- |
|
| Yancopoulos George |
Bd. Co-Chair, President & CSO |
• • – |
2025-12-09 |
4 |
D |
$701.51 |
$92,510,930 |
D/D |
(131,874) |
310,460 |
|
- |
|
| Yancopoulos George |
Bd. Co-Chair, President & CSO |
• • – |
2025-12-09 |
4 |
OE |
$555.67 |
$81,580,691 |
D/D |
146,815 |
442,334 |
|
- |
|
| Mccourt Marion |
EVP Commercial |
• – – |
2025-12-09 |
4 |
D |
$701.51 |
$716,242 |
D/D |
(1,021) |
14,349 |
|
- |
|
1271 Records found
|
|
Page 1 of 51 |
|
|
11.26 (1.39%) 
